Fentanyl in Angioplasty: What Is the Price of More Comfort During the Procedure?

Fentanyl is a potent opiate commonly administered in the cath lab. Recently, questions on its safety have been raised by research demonstrating that intravenous morphine significantly delays the absorption of oral P2Y12 platelet inhibitors. The mechanism might be slowed gastric emptying.

Fentanilo en la angioplatia: ¿Cuál es el precio de un mayor confort en el procedimiento?

The Platelet Aggregation with tiCagrelor Inhibition and FentanYl (PACIFY) trial enrolled 212 patients undergoing indicated angioplasty and randomized them to receive the procedure with or without fentanyl. Furthermore, all participants received subcutaneous lidocaine and intravenous midazolam besides 180 mg of ticagrelor as antiplatelet agent.


Read also: MitraClip Procedure Can Be Performed without General Anesthesia”.


Blood samples were taken in order to analyze the plasmatic concentration of ticagrelor 0.5, 1, 2, 4, and 24 hours after the load. Platelet function was also measured at 2 hours with the VerifyNow system.

 

The group receiving fentanyl presented significantly lower plasmatic concentrations of ticagrelor and higher platelet reactivity with the addition of ADP 2 hours after the load.

 

No differences in ticagrelor concentration were observed at 4 hours.


Read also: “The SOURCE 3 Confirms the Good Outcomes of the SAPIEN 3 at One Year Followup”.


In a pain survey with a 1-10 scale, patients who received fentanyl reported a 1.5 maximum pain vs. 2.3 reported by patients who did not receive the drug (p = 0.14).

 

One patient who received fentanyl experienced acute stent thrombosis and another presented catheter thrombosis. There were no thrombotic events in patients who did not receive fentanyl.

 

The post-procedural levels of ultra-sensitive troponin were significantly higher in the group receiving fentanyl, which raises questions on the clinical importance of the interaction between these drugs.

 

Conclusion

Routine use of fentanyl as part of sedation in coronary angioplasty reduces the absorption of ticagrelor and delays platelet inhibition, without comfort improvement as a counterpart.

 

Editorial

These results are added to the list of prior reports on how morphine delays the absorption of clopidogrel, prasugrel, and ticagrelor.

 

The prophylactic administration of fentanyl at the start of catheterization should be reconsidered.

 

Original title: Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial.

Reference: John W. McEvoy et al. Circulation. 2017 Oct 18. Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...

ACC 2026 | STEMI-Door To Unload: Unloading with Impella before PCI did not reduce infarct size in anterior STEMI

Anterior ST-segment elevation myocardial infarction (STEMI) remains associated with a high incidence of heart failure and mortality, even in the era of early reperfusion....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...